Drug intelligence / Profile preview

MA-20

Development stage: Discontinued
Modality: Recombinant Proteins and Enzymes
Administration: Infusion

Overview

MA-20 is a protein administered as a booster infusion in conjunction with ASP2802, a CAR-T cell therapy, for the treatment of CD20-positive B-cell lymphomas. It is designed to enhance the efficacy of the CAR-T cell therapy by helping it work more effectively inside the body. The drug is given in a 28-day cycle, with booster infusions on Day 3 and Day 17.

Beyond the preview

Go deeper on MA-20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MA-20.

Explore the full profile